Hexokinase 2 Inhibition Attenuates Microglial Activation and Neuronal Degeneration Following Traumatic Brain Injury
This study demonstrates that post-injury administration of the glycolytic inhibitor 3-bromopyruvic acid (3-BP) attenuates microglial activation and neuroinflammation while preserving hippocampal neuronal integrity and improving neurological and cognitive outcomes in a rat model of traumatic brain injury, suggesting that targeting hexokinase 2-related metabolic pathways offers a potential therapeutic strategy for limiting secondary brain injury.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When the brain suffers a severe blow, the damage does not stop when the impact ends. In the hours and days that follow, the brain launches a complex internal defense that can sometimes turn against itself. This secondary wave of injury involves the brain's own immune cells, which become overactive and release chemicals that harm healthy tissue. At the same time, the energy systems inside these cells shift into a high-speed, inefficient mode that fuels this destructive inflammation. Scientists have long suspected that if they could calm this metabolic fire, they might be able to protect the brain from further harm. The question has been whether a specific switch that controls this energy shift could be turned off to stop the damage without shutting down the brain's necessary repair work.
A team of researchers at Hallym University in South Korea set out to test this idea using a model of traumatic brain injury in rats. They focused on a protein called hexokinase 2, which acts as a gatekeeper for a specific type of energy production. Under normal conditions, brain cells use a steady, efficient process to generate power. However, when immune cells in the brain detect injury, they often switch to a faster, less efficient method that produces a lot of heat and chemical byproducts, much like a car engine revving wildly in neutral. This switch is driven by the hexokinase 2 protein. The researchers wanted to see if blocking this protein with a drug called 3-bromopyruvic acid could stop the immune cells from becoming destructive, thereby saving brain cells and improving recovery.
To investigate this, the team induced a controlled injury in the brains of adult rats, mimicking the kind of damage seen in human accidents. Immediately after the injury, they gave one group of rats a single injection of the drug, while another group received a harmless saltwater solution. They then watched closely to see what happened over the next week. The results showed that the drug worked exactly as the researchers hoped. In the brains of the treated rats, the levels of the hexokinase 2 protein dropped significantly compared to the untreated group. This reduction was accompanied by a noticeable calming of the brain's immune cells. Instead of swelling and becoming aggressive, these cells remained smaller and less active.
The study measured specific markers to confirm this change. The researchers found that the treated rats had far fewer signs of the immune cells eating up healthy tissue or releasing inflammatory chemicals that damage neurons. In the part of the brain responsible for memory and learning, known as the hippocampus, the drug prevented the death of brain cells that typically occurs after such an injury. While the untreated rats lost a significant number of these cells, the treated rats kept most of them intact. Furthermore, the structural connections between the brain cells, which are essential for communication, remained stronger in the animals that received the drug.
These physical changes translated into real-world improvements for the animals. The researchers tested the rats' ability to learn and remember by placing them in a pool of water with a hidden platform they needed to find. Rats that received the drug learned the location of the platform much faster than those that did not. They also showed better memory of where the platform had been when it was removed. In addition to these cognitive gains, the treated rats recovered their physical balance and coordination more quickly, showing fewer signs of neurological impairment in the days following the injury.
The findings suggest that targeting the energy metabolism of the brain's immune cells is a viable way to limit the secondary damage that follows a traumatic brain injury. By blocking the hexokinase 2 protein, the drug prevented the immune cells from entering a destructive, high-energy state. This allowed the brain to preserve its structure and function better than it did without treatment. The researchers noted that while the drug was effective, it is not a cure-all, and the study was limited to male rats and a short observation period. However, the results provide a clear path forward, indicating that managing the metabolic fuel of the brain's immune response could be a powerful new strategy for protecting the brain after trauma.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.